论文部分内容阅读
目的:观察阿奇霉素治疗COPD急性发作期合并支原体感染的临床效果。方法:选取本院2007年3月～2009年12月收治的126例COPD急性发作期合并支原体感染患者,随机分为观察组(阿奇霉素治疗组)和对照组(红霉素治疗组)各63例,比较两组患者的治疗效果及不良反应情况。结果:①观察组治愈45例,显效12例,有效4例,总有效率为90.5%;对照组治愈34例,显效11例,有效12例,总有效率为71.4%。两组患者比较差异有统计学意义(P<0.01)。②两组患者治疗过程中发生不良反应均较轻微,观察组发生恶心2例,对照组发生头昏1例,食欲不振1例,均未影响治疗。结论:阿奇霉素治疗COPD急性发作期合并支原体感染效果理想,且安全性较高。
Objective: To observe the clinical effect of azithromycin in the treatment of acute episode of COPD with mycoplasma infection. Methods: A total of 126 COPD patients with mycoplasma infection from March 2007 to December 2009 were randomly divided into observation group (azithromycin treatment group) and control group (erythromycin treatment group), 63 cases each , The treatment effect and adverse reaction of two groups were compared. Results: ① In the observation group, 45 cases were cured, 12 cases were markedly effective, 4 cases were effective, and the total effective rate was 90.5%. In the control group, 34 cases were cured, 11 cases were markedly effective and 12 cases were effective. The total effective rate was 71.4%. The difference between the two groups was statistically significant (P <0.01). ② The two groups of patients with adverse reactions during the treatment were minor, the observation group nausea in 2 cases, 1 case of dizziness in the control group, loss of appetite in 1 case, did not affect the treatment. Conclusion: Azithromycin is effective and safe in the treatment of acute episode of COPD with mycoplasma infection.